On November 11, 2024, Director Laurence Charney executed a significant transaction by selling 25,000 shares of TG Therapeutics Inc (TGTX, Financial). The sale was documented in an SEC Filing, with the shares priced at $30.2 each. Following this transaction, the insider now owns 207,479 shares of the company.
TG Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is based in New York, USA.
Over the past year, Laurence Charney has sold a total of 64,500 shares and has not made any purchases. This recent sale continues a trend observed over the last year, where there have been eight insider sells and no insider buys.
The company's shares were trading at $30.2 on the day of the sale, giving TG Therapeutics Inc a market cap of approximately $4.81 billion. According to the GF Value, the stock has a price-to-GF-Value ratio of 0.1, indicating it is a Possible Value Trap, Think Twice.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider activity and valuation metrics provide critical data points for investors monitoring TG Therapeutics Inc's stock performance and insider behaviors.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
